|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
|
AU662891B2
(en)
|
1990-11-27 |
1995-09-21 |
Biogen Idec Ma Inc. |
Anti CD-4 antibodies blocking HIV-induced syncytia
|
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
AU2589095A
(en)
|
1994-05-16 |
1995-12-05 |
Washington University |
Cell membrane fusion composition and method
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
WO1997034634A1
(en)
|
1996-03-20 |
1997-09-25 |
Sloan-Kettering Institute For Cancer Research |
Single chain fv constructs of anti-ganglioside gd2 antibodies
|
|
PT904392E
(pt)
|
1996-10-17 |
2001-06-29 |
Oxford Biomedica Ltd |
Vectores retrovirais
|
|
US7541034B1
(en)
|
1997-03-20 |
2009-06-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
|
|
GB9720465D0
(en)
|
1997-09-25 |
1997-11-26 |
Oxford Biomedica Ltd |
Dual-virus vectors
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
ES2373406T3
(es)
|
1997-12-22 |
2012-02-03 |
Oxford Biomedica (Uk) Limited |
Vectores basados en el virus de la anemia infecciosa equina (vaie).
|
|
GB9803351D0
(en)
|
1998-02-17 |
1998-04-15 |
Oxford Biomedica Ltd |
Anti-viral vectors
|
|
FR2777909B1
(fr)
|
1998-04-24 |
2002-08-02 |
Pasteur Institut |
Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
|
|
EP1109921A4
(en)
|
1998-09-04 |
2002-08-28 |
Sloan Kettering Inst Cancer |
FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
|
|
US6410319B1
(en)
|
1998-10-20 |
2002-06-25 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
GB0009760D0
(en)
|
2000-04-19 |
2000-06-07 |
Oxford Biomedica Ltd |
Method
|
|
US20020131960A1
(en)
|
2000-06-02 |
2002-09-19 |
Michel Sadelain |
Artificial antigen presenting cells and methods of use thereof
|
|
ATE338124T1
(de)
|
2000-11-07 |
2006-09-15 |
Hope City |
Cd19-spezifische umgezielte immunzellen
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
EP1395284B1
(en)
|
2001-06-14 |
2010-12-08 |
Isis Innovation Limited |
Non-depleting anti-CD4 antibody TRX1 and its uses
|
|
US7541443B2
(en)
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
|
US7355012B2
(en)
|
2001-09-26 |
2008-04-08 |
United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
US7982011B2
(en)
|
2003-11-25 |
2011-07-19 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
|
WO2005059111A2
(en)
|
2003-12-17 |
2005-06-30 |
The Trustees Of Columbia University In The City Of New York |
DELIVERY OF DNA OR RNA VIA GAP JUNCTIONS FROM HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SiRNA
|
|
CA2645322A1
(en)
|
2006-03-16 |
2007-09-27 |
Genentech, Inc. |
Methods of treating lupus using cd4 antibodies
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
EP2599791A1
(en)
|
2007-04-27 |
2013-06-05 |
Genentech, Inc. |
Potent, stable and non-immunosuppressive anti-CD4 antibodies
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
EP2331566B1
(en)
|
2008-08-26 |
2015-10-07 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
US9005963B2
(en)
|
2008-10-14 |
2015-04-14 |
Ablynx N.V. |
Amino acid sequences directed against cellular receptors for viruses and bacteria
|
|
PT2374883T
(pt)
|
2008-12-26 |
2016-10-20 |
Kyowa Hakko Kirin Co Ltd |
Anticorpo anti-cd4
|
|
MX341884B
(es)
|
2009-03-10 |
2016-09-07 |
Biogen Ma Inc |
Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
|
|
EP3957651A1
(en)
|
2010-05-21 |
2022-02-23 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
|
|
EP2471543A1
(en)
|
2010-12-02 |
2012-07-04 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CN102649818B
(zh)
|
2011-02-25 |
2014-10-08 |
厦门大学 |
抗cd4蛋白的单克隆抗体及其活性片段及用途
|
|
US9987308B2
(en)
|
2011-03-23 |
2018-06-05 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
WO2012156839A2
(en)
|
2011-05-19 |
2012-11-22 |
Ospedale San Raffaele S.R.L. |
New generation of splice-less lentiviral vectors for safer gene therapy applications
|
|
KR101972446B1
(ko)
|
2011-05-27 |
2019-04-25 |
글락소 그룹 리미티드 |
Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
|
|
CN103946952A
(zh)
|
2011-09-16 |
2014-07-23 |
宾夕法尼亚大学董事会 |
用于治疗癌症的rna改造的t细胞
|
|
CN104080797A
(zh)
|
2011-11-11 |
2014-10-01 |
弗雷德哈钦森癌症研究中心 |
针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
|
|
CA2861491C
(en)
|
2012-02-13 |
2020-08-25 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
EP2844746A4
(en)
|
2012-03-26 |
2016-07-20 |
Univ California |
PSEUDOTYPIZED LENTIVIRES WITH NIPAH VIRUS COVERS AND METHOD OF USE THEREOF
|
|
EP2844743B1
(en)
|
2012-05-03 |
2021-01-13 |
Fred Hutchinson Cancer Research Center |
Enhanced affinity t cell receptors and methods for making the same
|
|
US20150175678A1
(en)
|
2012-06-15 |
2015-06-25 |
Beth Israel Deaconess Medical Center, Inc. |
IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
|
|
BR122020002986A8
(pt)
|
2012-08-20 |
2023-04-18 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Método e composições para imunoterapia celular
|
|
MX370148B
(es)
|
2012-10-02 |
2019-12-03 |
Memorial Sloan Kettering Cancer Center |
Composiciones y su uso para inmunoterapia.
|
|
US9587022B2
(en)
|
2012-12-18 |
2017-03-07 |
The Rockefeller University |
Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CN113604491A
(zh)
|
2014-05-02 |
2021-11-05 |
宾夕法尼亚大学董事会 |
嵌合自身抗体受体t细胞的组合物和方法
|
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對ｃｄ１９具專一性之抗體及嵌合抗原受體
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
|
CN107921148A
(zh)
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
WO2018028647A1
(en)
|
2016-08-10 |
2018-02-15 |
Legend Biotech Usa Inc. |
Chimeric antigen receptors targeting bcma and methods of use thereof
|
|
US20180291080A1
(en)
|
2015-09-28 |
2018-10-11 |
Trustees Of Dartmouth College |
Chimeric antigen receptor, regulatory cells and methods of use
|
|
JP2018534264A
(ja)
|
2015-09-28 |
2018-11-22 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
|
|
TW201800459A
(zh)
|
2015-12-18 |
2018-01-01 |
富士軟片股份有限公司 |
近紅外線吸收組成物、近紅外線截止濾波器、近紅外線截止濾波器的製造方法、固體攝像元件、照相機模組及圖像顯示裝置
|
|
EP3235908A1
(en)
|
2016-04-21 |
2017-10-25 |
Ecole Normale Superieure De Lyon |
Methods for selectively modulating the activity of distinct subtypes of cells
|
|
MA45783A
(fr)
|
2016-07-29 |
2019-06-05 |
Juno Therapeutics Inc |
Procédés d'évaluation de la présence ou de l'absence d'un virus compétent pour la réplication
|
|
KR20190071677A
(ko)
|
2016-08-13 |
2019-06-24 |
유나이티드 바이오파마, 인크. |
Haart 안정화된 환자에서 cd4에 대한 항체에 의한 hiv 감염의 치료 및 지속적 바이러스 완화
|
|
WO2018156735A1
(en)
|
2017-02-22 |
2018-08-30 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bispecific antibody for cancer immunotherapy
|
|
WO2018170096A1
(en)
|
2017-03-14 |
2018-09-20 |
Dualogics, Llc |
Use of a cd4/cd8 bispecific antibody for the treatment of diabetes
|
|
CN110650975B
(zh)
|
2017-05-15 |
2024-04-05 |
美国卫生和人力服务部 |
双顺反子嵌合抗原受体及其用途
|
|
ES2928296T3
(es)
|
2017-06-30 |
2022-11-16 |
Us Health |
Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos
|
|
EP3674327A4
(en)
|
2018-02-01 |
2021-05-05 |
Nanjing Iaso Biotherapeutics Co., Ltd. |
BINDING OF CHIMERIC ANTIGEN RECEPTOR (CAR) TO BCMA AND USES THEREOF
|
|
US11807663B2
(en)
|
2018-02-01 |
2023-11-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof
|
|
PT3674328T
(pt)
|
2018-02-01 |
2024-03-14 |
Innovent Biologics Suzhou Co Ltd |
Recetor de antigénio quimérico (car) que se liga a bcma e utilizações do mesmo
|
|
KR102721494B1
(ko)
|
2018-04-17 |
2024-10-24 |
국립암센터 |
고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도
|
|
SG11202011015QA
(en)
|
2018-05-15 |
2020-12-30 |
Flagship Pioneering Innovations V Inc |
Fusosome compositions and uses thereof
|
|
WO2019236684A1
(en)
|
2018-06-08 |
2019-12-12 |
Imaginab, Inc. |
Antigen binding constructs to cd4
|
|
IL279354B1
(en)
|
2018-06-21 |
2026-02-01 |
Regeneron Pharma |
Bispecific antibodies against psma and against cd28 and their uses
|
|
CN112955174A
(zh)
|
2018-07-09 |
2021-06-11 |
旗舰先锋创新V股份有限公司 |
融合剂脂质体组合物和其用途
|
|
US11939377B2
(en)
|
2018-07-12 |
2024-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
|
JP7462621B2
(ja)
|
2018-10-09 |
2024-04-05 |
サノフイ |
三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
|
|
EP3880832A1
(en)
|
2018-11-14 |
2021-09-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
|
US20220008557A1
(en)
|
2018-11-14 |
2022-01-13 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for cns delivery
|
|
AU2019378883A1
(en)
|
2018-11-14 |
2021-06-03 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for T cell delivery
|
|
MA54540A
(fr)
|
2018-12-19 |
2021-10-27 |
Regeneron Pharma |
Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
|
|
US11453721B2
(en)
|
2018-12-19 |
2022-09-27 |
Regeneran Pharmaceuticals, Inc. |
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
|
|
WO2020127628A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
UA128001C2
(uk)
|
2018-12-21 |
2024-03-06 |
Ф. Хоффманн-Ля Рош Аг |
Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
|
|
CA3134335A1
(en)
|
2019-03-22 |
2020-10-01 |
Regeneron Pharmaceuticals, Inc. |
Egfr x cd28 multispecific antibodies
|
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
|
AU2020275049A1
(en)
|
2019-05-16 |
2022-01-06 |
Nanjing Legend Biotech Co., Ltd. |
Engineered immune cells comprsing a recognition molecule
|